Phaseline

Companies › Polarean

Polarean: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 3; Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Albuterol Sulfate
Beta-2 adrenergic receptor agonist
ADRB2Phase 1Chronic Obstructive Pulmonary Disease; BronchiolitisDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06271408Albuterol SulfatePhase 1Chronic Obstructive Pulmonary DiseaseRespiratoryDec 2026
NCT06946264Albuterol SulfatePhase 3BronchiolitisRespiratoryDec 2029

From the company's SEC filings

Complete response letters from FDA

Targets

ADRB2 (1)

Companies with the same targets

Chiesi Farmaceutici AstraZeneca GSK Lunan Better Pharmaceutical Actimed Therapeutics ARS Pharmaceuticals Novartis EyeD Pharma Acer Therapeutics Teva Branded Pharmaceutical Products R&D

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.